1. Home
  2. ARL vs ZNTL Comparison

ARL vs ZNTL Comparison

Compare ARL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Realty Investors Inc.

ARL

American Realty Investors Inc.

HOLD

Current Price

$21.12

Market Cap

261.7M

Sector

Real Estate

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$4.49

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARL
ZNTL
Founded
1999
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.7M
289.0M
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
ARL
ZNTL
Price
$21.12
$4.49
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$6.60
AVG Volume (30 Days)
11.6K
1.2M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
206.59
18.03
EPS
N/A
N/A
Revenue
$50,014,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.70
N/A
52 Week Low
$12.42
$1.15
52 Week High
$24.44
$6.95

Technical Indicators

Market Signals
Indicator
ARL
ZNTL
Relative Strength Index (RSI) 69.62 59.31
Support Level $14.97 $3.53
Resistance Level N/A $6.95
Average True Range (ATR) 1.10 0.38
MACD 0.68 0.10
Stochastic Oscillator 67.14 60.37

Price Performance

Historical Comparison
ARL
ZNTL

About ARL American Realty Investors Inc.

American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: